Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Somaxon To Put Silenor Phase III Program To Bed In December

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm's Q3 2007 filing timeframe puts it ahead of Neurocrine's resubmission plans for immediate-release indiplon.
Advertisement

Related Content

Somaxon Pushes Back Insomnia Drug Silenor NDA Filing To Q1 2008
Somaxon Pushes Back Insomnia Drug Silenor NDA Filing To Q1 2008
Vanda Moves Ahead With Development Of Iloperidone, VEC-162
Vanda Moves Ahead With Development Of Iloperidone, VEC-162
Silenor’s Bleary Regulatory Timeline May Clear Up
Vanda Atypical Antipsychotic Shows Apparent Genetic Response In Phase III
Somaxon Could Fold Gambling Drug Development Following Negative Trial Results
Neurocrine Delays Indiplon Resubmission To Run Confirmatory Trial
Somaxon To Conduct Preclinical Tests On Its Phase III Insomnia Drug Silenor
Somaxon To Conduct Preclinical Tests On Its Phase III Insomnia Drug Silenor

Topics

Advertisement
UsernamePublicRestriction

Register

PS063426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel